In this study, Relora significantly reduced short-term anxiety compared to the placebo group. The subjects reported that they have suffered from anxiety and they typically eat more in response to stressful situations. The intervention was 250mg capsules of Relora or identical placebo three times daily for six weeks. Short-term anxiety was measured by the Spielberger State questionnaire. There were no safety concerns or significant adverse events observed in the study.
Charles Kosmont, chairman and CEO of Next Pharmaceuticals, said: “This is the first clinical study on Relora involving healthy women. Because the trial was geared towards this demographic, our customers can now promote Relora to a larger consumer base. There are many who suffer from short-term anxiety that do not want to be on medication. Relora may be the perfect alternative.”